An extension to the current
Dr
'We have carefully reviewed clinical trial data in children aged 12 to 15 years and have concluded that the
'We have in place a comprehensive safety surveillance strategy for monitoring the safety of all
'No extension to an authorisation would be approved unless the expected standards of safety, quality and effectiveness have been met.
'It will now be for the
Professor
'We have been very careful to take into consideration the younger age group and the benefits of this population being vaccinated against any potential risk of side effects. There has been a thorough assessment and review of this data which was also looked at specifically by the
'We have concluded that based on the data we have seen on the quality, effectiveness and safety of the vaccine, its benefits do outweigh any risk. The MHRA will continue to scrutinise all of the suspected side effects data received through the rigorous surveillance programme in place through the Yellow Card scheme and other safety surveillance measures for all of the COVID-19 vaccines used in the
'Over 2000 children aged 12-15 years were studied as part of the randomised, placebo-controlled clinical trials. There were no cases of COVID-19 from 7 days after the second dose in the vaccinated group, compared with 16 cases in the placebo group. In addition, data on neutralising antibodies showed the vaccine working at the same level as seen in adults aged 16-25 years. These are extremely positive results.'
Background
The
No new side effects were identified and the safety data in children was comparable with that seen in young adults. As in young adults, the majority of adverse events were mild to moderate and relating to reactogenicity, such as a sore arm or tiredness.
More information can be found in the Product Information for the
The Medicines and Healthcare products Regulatory Agency is responsible for regulating all medicines and medical devices in the
The Medicines and Healthcare products Regulatory Agency ('the agency') has three centres. The MHRA, the
Contact:
Media
News centre
MHRA
10
E14 4PU
Email: newscentre@mhra.gov.uk
During office hours: 020 3080 7651 (08:30 - 17:00)
Out of office hours: 07770 446 189 (17:00 - 08:30)
Office hours are Monday to Friday,
(C) 2021 Electronic News Publishing, source